Board of Directors

Board of Directors

Members of the Cyxone board have extensive experience of taking projects from academic research stage to publicly traded development companies, fundraising as well as negotiating license and cooperation agreements.

Bert Junno

Chairman of the Board

Born 1966. Chairman of the Board since 2015.

Experiences

Dr Junno has previous management and board level experience from several European and US based companies in fields of electronics, biotech and IT. He has also co-founded several life science companies, for example WntResearch AB (publ), Galecto Biotech AB, Gabather AB (publ), Aptahem AB (publ) and Cyxone AB (publ). Dr Junno holds a Ph.D. in Semiconductor Physics and Technology and a M.Sc. in Physics from Lund University.

Other assigments

  • Owner and active in Accequa AB
  • Chairman of the Board in CombiGene AB (publ)
  • Chairman of the Board in Aptahem AB (publ)
  • Board Member in Accequa AB
  • Board Member in Accequa GmbH

Previous assignments

  • Board Member in Gabather AB (publ)
  • Board Member in Gabather Finans AB
  • CEO in Gabather AB (publ)
  • Member of the Advisory Board of the Swedish Intellectual Property Office

Shares in the company (as per 8 March 2021)

Bert Junno owns 400,000 shares in Cyxone. Junno further owns 33% of Accequa, which owns 5,962,500 shares in Cyxone.

Theresa Comiskey Olsen

Board Member

Born 1963. Board Member since 2016.

Experiences

Theresa Comiskey Olsen, Attorney at Law (USA), is a Partner at Nova Law Firm in Oslo, Norway. Before joining Nova, Comiskey Olsen was a partner at Langseth Law Firm since January 2016 after starting her own practice with focus on legal transactions in the Life Sciences/Biotech field. Prior to starting her practice in 2008, she was General Counsel of Nycomed, which has since been acquired by Takeda. Comiskey Olsen continues to grow her practice at Nova with focus on legal transactions in the Life Sciences/Biotech field. She has her B.A. from University of Pennsylvania and her J.D. from University of Detroit Mercy School of Law.

Other assignments

  • Board Member in FF Bygg og Vedlikehold AS
  • Board Member in Jotunfjell AS
  • Board Member in Aptahem AB (publ)
  • Board Member in Farma Investment AS
  • Owner and partner in Advokatfirmaet Nova DA

Previous assignments

  • Board Member in PCI Biotech Holding ASA
  • Board Member in Calpro AS
  • Board Member in Nordic Nanovector ASA
  • Board Member in Serodus ASA
  • Board Member in Biovotec AS
  • Owner and partner in Langseth Advokatfirma DA
  • Chairman of the Board in MyLifeProducts AS

Shares in the company (as per 14 April 2020)

Theresa Comiskey Olsen owns 100,000 shares in Cyxone

Saad Gilani

Board Member

Born 1971. Board Member since 2015.

Experiences

Saad Gilani is a Managing Director at Yorkville Advisors Global and has been with the firm since 2005. As Head of the Healthcare Group, he has led financing transactions in a variety of life science companies focused on biotechnology, molecular diagnostics and medical devices in the US and in Europe. Gilani is a member of the firm’s Investment Committee. He also sits on the supervisory board of Temple Therapeutics BV based in The Netherlands.

Prior to joining Yorkville Advisors Global, Gilani worked at Keyence Corporation for 11 years where he held various management roles within the Engineering and Marketing groups. He earned a BSc in Electrical Engineering from Rutgers College of Engineering and received his MBA from Rutgers University in NJ, where he specialized in finance.

Other assignments

  • Board Member in Temple Therapeutics BV

Shares in the company (as per 14 April 2020)

Saad Gilani owns 132,500 shares in Cyxone

Mikael Lindstam

Board Member

Born 1966. Board Member since 2015.

Experiences

Mikael Lindstam has been engaged in several start-up companies and development programs that have generated investments of more than 250 MSEK. Dr. Lindstam has been part of the development of Galecto Biotech AB, Gabather AB and Aptahem AB from Forskarpatent’s portfolio including a number of license deals and IP-divestments. Dr. Lindstam is a co-founder of Accequa AB and is currently board member and CEO of Aptahem AB and holds a Ph.D. in inorganic chemistry and with long experience from marketing, entrepreneurship and management.

Other assignments

  • Owner and active in Accequa AB
  • Chairman of the Board in Accequa AB
  • Board Member in Aptahem Finans AB
  • Board Member in Accequa GmbH

Previous assignments

  • Board Member in Ceratmo AB

Shares in the company (as per 18 September 2020)

Mikael Lindstam owns 62,500 shares in Cyxone. Lindstam further owns 33% of Accequa, which owns 5,962,500 shares in Cyxone.